Top Markets
#1 TENDIES TENDIES +59.72%
#2 Threshold Network Threshold Network +48.06%
#3 Cash Cat Cash Cat +25.61%
#4 Akedo Akedo +23.45%
#5 OSK OSK +16.28%
#6 Kinetiq Kinetiq +15.49%
#7 Maple Finance Maple Finance +14.59%
#8 Ape and Pepe Ape and Pepe +12.62%
#9 Falcon Finance Falcon Finance +12.36%
#10 Magma Finance Magma Finance +12.35%
Coin of the day
TENDIES TENDIES
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Neumora Therapeutics, Inc. Common Stock Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock

NMRA
Classement en actions #17294
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company... Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
Prix de l'action
$1.33
Dernière synchronisation: 2026-09-01
Capitalisation boursière
$246.43M
Changement (1 jour)
0.00%
Changement (1 an)
-23.56%
Pays
US
Échange Neumora Therapeutics, Inc. Common Stock (NMRA)

Catégorie

Healthcare
Ratio P/B pour Neumora Therapeutics, Inc. Common Stock (NMRA)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Neumora Therapeutics, Inc. Common Stock, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Neumora Therapeutics, Inc. Common Stock de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.828 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.5116 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.2199 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9942 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH